Consano Bio to Present at BIO Investment & Growth Summit 2026
BURLINGTON, MA — February 23, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that CEO Andrew Hall will present at the BIO Investment & Growth Summit, taking place March 2–3, 2026, in Miami, Florida. READ MORE
Consano Bio Highlights Scientific Advisory Board Supporting Clinical Development of C-1101 for Chronic Sciatica
BURLINGTON, MA — February 13, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101 into clinical development for chronic lumbosacral radiculopathy (LSR), or chronic sciatica. READ MORE
Consano Bio Presents Favorable Nonclinical Safety Results for C-1101 at the American College of Toxicology 46th Annual Meeting
BURLINGTON, MA — November 21, 2025 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced positive data from its nonclinical safety and toxicology program for C-1101, supporting initiation of a Phase 1 clinical trial in patients with chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The results were presented in a poster at the American College of Toxicology (ACT) 46th Annual Meeting in Phoenix, AZ. READ MORE
CORPORATE PRESENTATION
